| Chronic Kidney Diseases
Kerendia vs Xphozah
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Kerendia vs Xphozah 10 Mg with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXphozah 10 Mg has a higher rate of injection site reactions vs Kerendia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xphozah 10 Mg but not Kerendia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kerendia
Xphozah 10 Mg
At A Glance
Oral
Once daily
Mineralocorticoid receptor antagonist
Oral
Twice daily
NHE3 inhibitor
Indications
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Chronic kidney disease stage 5
- Myocardial Infarction
- Chronic Kidney Diseases
Dosing
Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.
Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.
Chronic Kidney Diseases 30 mg orally twice daily, taken just prior to the first and last meals of the day; monitor serum phosphorus and adjust dosage as needed for gastrointestinal tolerability.
Contraindications
- Hypersensitivity to any component of Kerendia
- Concomitant treatment with strong CYP3A4 inhibitors
- Adrenal insufficiency
- Age under 6 years due to risk of diarrhea and serious dehydration
- Known or suspected mechanical gastrointestinal obstruction
Adverse Reactions
Most common (>=10%) hyperkalemia
Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure
Postmarketing angioedema, rash, urticaria
Most common (>=5%) Diarrhea (43-53% of patients)
Postmarketing Pruritis, rash, urticaria
Pharmacology
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
NHE3 inhibitor; tenapanor is a locally acting inhibitor of sodium/hydrogen exchanger 3 (NHE3), an antiporter on the apical surface of intestinal epithelium, whose inhibition reduces sodium absorption and decreases phosphate absorption by reducing paracellular phosphate permeability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kerendia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
Xphozah 10 Mg
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Kerendia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Xphozah 10 Mg
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Kerendia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Xphozah 10 Mg
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Bayer US Patient Assistance Foundation - KerendiaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Xphozah 10 Mg.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KerendiaView full Kerendia profile
Xphozah 10 MgView full Xphozah 10 Mg profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.